Kayexalate and Pomalyst drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Kayexalate (sodium polystyrene sulfonate) and Pomalyst (pomalidomide). Common drug interactions include platelet count decreased among females and bronchitis among males.

The phase IV clinical study analyzes what interactions people have when they take Kayexalate and Pomalyst. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Kayexalate?

Kayexalate has active ingredients of sodium polystyrene sulfonate. eHealthMe is studying from 5,004 Kayexalate users. Check the latest studies of Kayexalate.

What is Pomalyst?

Pomalyst has active ingredients of pomalidomide. eHealthMe is studying from 80,400 Pomalyst users. Check the latest studies of Pomalyst.

On Jul, 25, 2026

20 people who take Kayexalate and Pomalyst together, and have interactions are studied.

Kayexalate and Pomalyst drug interactions.

What are the common drug interactions of Kayexalate and Pomalyst, by gender? *:

female:

Platelet count decreased
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Plasma cell myeloma (cancer that begins in plasma cells)
Blood potassium decreased
Hepatitis fulminant (life-threatening condition defined by significantly impaired liver function)
Lymphocyte count decreased
Red blood cell count decreased
Sepsis (a severe blood infection that can lead to organ failure and death)
Syncope (loss of consciousness with an inability to maintain postural tone)
White blood cell count decreased

male:

Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Gastroenteritis (inflammation of stomach and intestine)
Basal cell carcinoma (a skin cancer, it rarely metastasizes or kills)
Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
Sepsis (a severe blood infection that can lead to organ failure and death)
Fall
Wound
Dizziness
Loss of consciousness
Neuropathy peripheral (surface nerve damage)

What are the common drug interactions of Kayexalate and Pomalyst, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Sepsis (a severe blood infection that can lead to organ failure and death)
Plasma cell myeloma (cancer that begins in plasma cells)
Lymphocyte count decreased
Red blood cell count decreased
Syncope (loss of consciousness with an inability to maintain postural tone)
White blood cell count decreased
Dizziness
Loss of consciousness
Neuropathy peripheral (surface nerve damage)
Rash

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 20 people, 100.00%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 2 people, 10.00%
Pain: 2 people, 10.00%
Nausea And Vomiting: 2 people, 10.00%
Nausea (feeling of having an urge to vomit): 2 people, 10.00%
Hyperkalemia (damage to or disease of the kidney): 2 people, 10.00%
Hepatitis B: 2 people, 10.00%
Anaemia (lack of blood): 2 people, 10.00%
Acute Kidney Failure: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Kayexalate and Pomalyst?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously